Combination of oral capecitabine and vinorelbine in metastatic breast cancer: A retrospective analysis of activity and tolerability profile
| Autor: | M. Ingemi, P. Spadaro, M. Iorfida, H. Soto Parra, C. Arcana |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research Chemotherapy medicine.medical_specialty Performance status business.industry medicine.medical_treatment macromolecular substances Vinorelbine medicine.disease Metastatic breast cancer carbohydrates (lipids) Capecitabine stomatognathic diseases Breast cancer Tolerability Internal medicine otorhinolaryngologic diseases medicine bacteria business Adjuvant medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:e11049-e11049 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e11049 Background: The purpose of this study was to retrospectively analyze toxicity profile and activity of an all-oral combination schedule of capecitabine (Cape) and vinorelbine (VNR) in metastatic breast cancer (MBC) patients (pts). Methods: All 60 pts treated had a histological confirmed diagnosis of breast cancer (BC). Each 3-week cycle of treatment consisted of 500 mg/m2 cape twice daily (2 weeks on, 1 week off), and 60 mg/m2 VNR on days 1 and 8. Results: From June 2007 to December 2010 we treated 60 MBC pts. Median age was 49 years (range 33-73). 42 pts (70%) had a performance status (PS) ECOG 0; 12 pts (20%) PS 1, 6 pts (10%) PS 2. 12 pts (20%) had metastatic disease at time of diagnosis. 52 (86,5%) expressed estrogenic receptor (ER); 10 pts (16,6%) had a HER2-positive disease; 38 (63,3%) HER-2 negative; 4 pts (6,66%) had a triple negative disease. 38 pts (63,3%) received adjuvant (adj) hormonal therapies (HT); 44 pts (73,3%) adj/neoadj chemotherapy (CT). Median time to recurrence was 37 months (... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|